Cero Therapeutics Appoints New CMO, CSO, and Directors
Ticker: CEROW · Form: 8-K · Filed: Dec 6, 2024 · CIK: 1870404
Sentiment: neutral
Topics: management-change, board-election, personnel
TL;DR
Cero Therapeutics beefs up leadership with new CMO, CSO, and board members.
AI Summary
Cero Therapeutics Holdings, Inc. announced on December 2, 2024, the appointment of Dr. Jonathan G. Y. Chen as Chief Medical Officer and Dr. David M. R. Hall as Chief Scientific Officer. The company also reported the election of Ms. Sarah E. Kelly and Mr. David M. R. Hall to its Board of Directors. These changes are effective immediately.
Why It Matters
The appointment of key scientific and medical leadership, along with new board members, signals a strategic shift or strengthening of Cero Therapeutics' research and development capabilities.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can indicate strategic shifts or internal challenges, requiring closer monitoring of the company's direction and performance.
Key Players & Entities
- Cero Therapeutics Holdings, Inc. (company) — Registrant
- Jonathan G. Y. Chen (person) — Appointed Chief Medical Officer
- David M. R. Hall (person) — Appointed Chief Scientific Officer and Elected to Board of Directors
- Sarah E. Kelly (person) — Elected to Board of Directors
- December 2, 2024 (date) — Effective date of appointments and elections
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Jonathan G. Y. Chen has been appointed as the new Chief Medical Officer.
Who has been appointed as the new Chief Scientific Officer?
Dr. David M. R. Hall has been appointed as the new Chief Scientific Officer.
Who has been elected to the Board of Directors?
Ms. Sarah E. Kelly and Mr. David M. R. Hall have been elected to the Board of Directors.
What is the effective date of these changes?
The changes are effective as of December 2, 2024.
What was Cero Therapeutics Holdings, Inc. formerly known as?
Cero Therapeutics Holdings, Inc. was formerly known as Phoenix Biotech Acquisition Corp.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-12-06 09:15:27
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CERO NASDAQ Global Market
Filing Documents
- ea0223559-8k_cerotherap.htm (8-K) — 29KB
- ea022355901ex99-1_cero.htm (EX-99.1) — 10KB
- 0001213900-24-106240.txt ( ) — 259KB
- cero-20241202.xsd (EX-101.SCH) — 4KB
- cero-20241202_def.xml (EX-101.DEF) — 26KB
- cero-20241202_lab.xml (EX-101.LAB) — 36KB
- cero-20241202_pre.xml (EX-101.PRE) — 25KB
- ea0223559-8k_cerotherap_htm.xml (XML) — 6KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements As previously disclosed, on October 2, 2024 the Board of Directors (the "Board") of CERo Therapeutics Holdings, Inc. (the "Company") appointed Chris Ehrlich as Interim Chief Executive Officer. On December 2, 2024, the Board approved the appointment of Mr. Ehrlich as Chief Executive Officer on a permanent, non-interim basis effective immediately. In connection with Mr. Ehrlich's appointment as the Company's permanent Chief Executive Officer, the Company intends to modify the terms of its existing consulting agreement with Mr. Ehrlich. Such terms will be reported on a Current Report on Form 8-K once agreed.
01 Other Events
Item 8.01 Other Events. On December 6, 2024, the Company issued a press release announcing Mr. Ehrlich's appointment as the Chief Executive Officer. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are furnished herewith: Exhibit No. Description 99.1 Press release, dated December 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 6, 2024 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Chief Executive Officer 2